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Abstract
Background: Colon cancer treatment is dependent on the stage at diagnosis. The current Tumor-Node-Metastasis (TNM) staging
for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision
making for chemotherapy will result in reducing over- and undertreatment. We developed a new, easy-to-apply, practice-changing
method to select colon cancer patients for adjuvant chemotherapy: the tumor-stroma ratio (TSR). The TSR distinguishes within
stage II-III patients who will likely benefit from adjuvant chemotherapy and those who will not.
Objective: The aim of the study was to add, in addition to the TNM classification, the TSR to current routine pathology evaluation.
Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicenter
study will validate the parameter prospectively.
Methods: The study is designed for future implementation of the TSR to the current TNM guidelines, using routinely
Haematoxylin- and Eosin-stained tumor tissue sections. In part 1 of the study, an electronic learning (e-learning) module with a
quality assessment program using the European Society of Pathology framework will be developed. This module will be used to
assess the reliability and reproducibility of the TSR, conducted by national and international pathologists. Part 2 will involve the
validation of the TSR in a prospective cohort of colon cancer p-stage II-III patients in a multicenter setting. In total, 1500 patients
will be included.
Results: The results of part 1 will be expected in the first half of 2019. For part 2, the inclusion of patients in the prospective
study, which started at the end of 2018, will take 3 years with an additional follow-up after another 3 years.
Conclusions: The main endpoints of this study are as follows: in part 1, trained (international) pathologists who are able to
reliably score the TSR, resulting in low intra- and interobserver variation; in part 2, confirmation of significant survival differences
for patients with a stroma-high tumor versus patients with a stroma-low tumor. On the basis of these findings, a modification in
current treatment guidelines will be suggested.
Trial Registration: Netherlands Trial Register NTR7270; https://www.trialregister.nl/trial/7072
International Registered Report Identifier (IRRID): DERR1-10.2196/13464
(JMIR Res Protoc 2019;8(6):e13464)   doi:10.2196/13464
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Introduction
Background
Despite complete resection of the primary tumor and
surrounding lymph nodes, colon cancer patients often develop
recurrence of disease, caused by the remaining micrometastases.
These can be treated with chemotherapy. However, as
micrometastases are difficult to detect, treatment guidelines are
usually based on tumor characteristics related to disease
progression and survival, such as depth of invasion and lymph
node metastasis. The current guidelines advise to give adjuvant
chemotherapy to patients with stage III colon carcinoma and
patients with stage II and one or more high-risk factors [1]. Only
a part of the patients who are treated with chemotherapy will
actually benefit. Furthermore, there is also substantial
undertreatment because 25% of the stage II patients, who do
not receive adjuvant chemotherapy, will develop recurrence or
metastasis within 5 years [2]. Some patients with stage IIIA
receive adjuvant chemotherapy, whereas in some cases, the
prognosis is better compared with patients with stage IIB disease
[1]. The selection of colon cancer patients for adjuvant treatment
should be further improved to establish an optimal treatment
regimen for each patient.
Over the last decade, the microenvironment or stromal (ie,
nonepithelial) component of tumors has been studied intensively.
There is increasing evidence that the tumor stroma plays an
important role in the biological behavior of tumors, their growth,
ability to metastasize, but also their response or resistance to
anticancer drugs [3-6]. Tumors that are rich in stroma behave
in a more aggressive way compared with tumors with little
stroma [2,7].
Tumor-Stroma Ratio
The tumor-stroma ratio (TSR) parameter is based on the amount
of stroma within the primary tumor and can be determined,
without extra costs, during routine pathology assessment. Using
the TSR, stage II/III stroma-high (high-risk) patients can be
adequately registered for treatment with chemotherapy, whereas
for the (elderly) patients with stage III and stroma-low, further
discussion is needed as to whether adjuvant therapy will benefit
these patients. New guidelines for patient management will have
consequences for better patient management leading to a more
optimal selection for adjuvant chemotherapy with a potential
reduction in costs.
A high stroma percentage (>50%) is an unfavorable prognostic
factor. The TSR has been validated in various international
studies with high interobserver agreements [2,7-12]. The TSR
was discussed by the TNM Evaluation Committee, the Union
for International Cancer Control, and the College of American
Pathologists. They stated that our observations are important
and novel and have the potential to be added to the TNM staging
algorithm as prognosticator. They advocated validation in a
prospective multicenter study and development of consensus
agreement and a quality assessment program. This protocol
elaborates on this recommendation.
Objectives
The overall objective is the addition of the TSR to current
routine pathology next to the TNM classification for clinical
decision making.
Primary objective for each part of the project:
1. Part 1: To evaluate and improve the reliability and
reproducibility of pathologists specifically instructed for
TSR scoring.
2. Part 2: To confirm the prognostic power of the method to
select patients at risk for the development of recurrence of
disease resulting in high-level evidence for adaptation of
guidelines.
Methods
Histopathological Scoring of the Tumor-Stroma Ratio
For the evaluation of the TSR, Haematoxylin and Eosin
(H&E)–stained sections of the primary colon carcinoma, used
in routine pathology to determine the T-stage (ie, the deepest
part of the tumor), are analyzed using conventional microscopy.
Areas with the largest amount of stroma are selected using a
2.5x or 5x objective. An area where both tumor and stromal
tissue are present within this vision site is selected using a 10x
objective. Tumor cells have to be present at all borders of the
selected image field. Mucinous tumors, although more difficult,
can also be scored; an area containing mucus may be used.
However, the volume of mucus should be excluded when
determining the TSR. Other challenging cases can be tumors
with abundant necrosis and/or muscle tissue in between tumor
glands. Necrotic areas or muscle tissue should be avoided in
the scoring procedure. It is not necessary to score the TSR at
the invasive front, picking a field with as much stroma as
possible is more accurate.
Stroma-high is defined as >50% stromal area and stroma-low,
as ≤50% stromal area in the histological section (Figure 1). This
cut-off has been determined a priori with maximum
discriminative power [2,7,9]. Even if there is only one image
field with a stroma-high score, this image field is decisive to
categorize the patient as stroma-high.
The scoring protocol is available in an instruction movie on the
Uniform Noting for International application of the
Tumor-stroma ratio as Easy Diagnostic tool (UNITED) study
website [13] and in written form published by our group [14].
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Figure 1. Examples of stroma-low colon cancer (A) and stroma-high colon cancer (B).
Study Design
Part 1 will consist of an electronic learning (e-learning) module
which has been developed with a quality assessment program
in the framework of the European Society of Pathology (ESP)
External Quality Assessment program. Using this module, a
reliability and reproducibility study on H&E-stained tumor
tissues will be conducted among national and international
pathologists.
Part 2 will involve validation in a prospective cohort of colon
cancer stage II-III patients within this multicenter setting. The
inclusion is expected to take 3 years, with a 3-year follow-up
period.
Patient Description
In the UNITED study, all patients are diagnosed with
pathological stage (p-stage) II or p-stage III colon cancer. For
e-learning, H&E-stained slides of stage II-III colon cancer
patients were selected in a retrospective manner. Material was
obtained from the archive of the Department of Pathology of
the Leiden University Medical Center (LUMC).
Part 1: The E-Learning Module
An e-learning module has been developed in the framework of
the ESP. The software used for the e-learning is PathXL Tutor
version 6.1.1.1. (Philips). This is a Web-based software that can
be accessed worldwide. Participating pathologists receive
specific user credentials for access to the e-learning sets. The
workflow is shown in Figure 2 and includes an introduction
film with the technical instructions. Hereafter, the participating
pathologists may start the e-learning by analyzing the training
set containing 40 cases.
TSR scores of participating pathologists will be compared with
a reference score (consisting of 3 observers at the LUMC). If a
pathologist does not pass a set (interobserver variability
kappa<.70), he or she is asked to re-analyze the set. If need be,
the instruction video and protocol can be studied again. If a
pathologist passes the set (kappa≥.70), the pathologist is able
to continue to the next set of 40 slides. The test set will be
repeated after 2 months, thereafter inter- and intraobserver
variability are determined. The pathologists are unaware of any
clinical information or previous scoring.
The quality of TSR scoring by the participating pathologists
will be monitored on a yearly basis by offering control series.
Part 2: Validation of the Tumor-Stroma Ratio in a
Prospective Study
After finishing the e-learning, the pathologist is well instructed
to score TSR in the daily routine. To validate the TSR
prospectively, a multicenter study is set up. The study aims to
include, in the participating centers, a total of 1500 colon cancer
patients who have undergone complete curative resection (R0
resection), independent of receiving adjuvant chemotherapy
according to actual guidelines.
Recruitment of Patients and Consent
Each consecutive eligible patient with a clinical stage I/II/III
tumor will be informed about the study by their physician or
research nurse. After informed consent, the pathologist is
notified that the TSR can be determined. All patients,
independent of gender and family history, are invited to
participate. Medical history is no reason for exclusion, apart
from malignancies within 10 years before the current colon
carcinoma. Textboxes 1 and 2 describe the inclusion and
exclusion criteria.
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Figure 2. Flowchart for the instruction of participating pathologists using the e-learning module.
Textbox 1. Patient inclusion criteria.
• Histologically proven colon carcinoma
• Complete curative resection (R0 resection)
• Clinical stage I (T1-2, N0, M0), II (T3-4, N0, M0) or III (any T, N1-2, M0)
• Aged ≥18 years
• Written informed consent
Textbox 2. Patient exclusion criteria.
• Neo-adjuvant treatment; this influences the amount of tumor and stroma, by fibrosis formation
• Any malignancy within 10 years before the current colon carcinoma (except for basal cell carcinoma or cervical carcinoma in situ) or any colon
carcinoma in history; owing to prolonged treatment or metastasis from earlier primary tumors that can influence the current colon carcinoma
prognosis. Basal cell carcinoma and cervical carcinoma in situ do not have metastatic capacity
• Multiple synchronous colon tumors; patients with synchronous tumors are likely to have a worse prognosis and need a different approach for
treatment
• Rectum tumors; these are defined as separate entities. Prognosis and treatment is different compared with colon tumors
Additional exclusion after surgery:
• p-stage I or stage IV; p-stage I is excluded as these patients will not receive adjuvant treatment. Stage IV patients are excluded as these patients
are palliatively treated
• Deceased within 3 months after surgery; patients who die within 3 months after surgery die most often owing to comorbidity or surgical
complications
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Safety Reporting and Risk Analysis
The patient material to be analyzed in this study is a
conventional H&E-stained histological section of the primary
tumor, obtained during the routine pathology process. The
method is without any additional intervention and the study
does not have consequences for the treatment of patients.
Therefore, the safety or health of participating subjects will not
be jeopardized in any way by this study. Consequently, no
adverse events, serious adverse events, or suspected unexpected
serious adverse events will occur owing to the study. A data
safety monitoring board is not indicated.
Data Storage
The LUMC Datacenter, Department of Surgery, is the Central
Datacenter and responsible for supply of electronic Case Report
Forms, study database, generation of queries within the database,
and central monitoring.
Data will be stored in Castor Electronic Data Capture (Castor
EDC; Castor, Amsterdam, the Netherlands) [15]. Castor EDC
is a cloud-based electronic data capture platform, easy-to-use
by researchers worldwide and highly secured. Data can be easily
captured; therefore, data are of high quality and reusable. Data
and documents will be stored for at least 15 years.
Statistical Analysis
Statistical analysis will be performed using IBM SPSS Statistics
version 25.0 in collaboration with the Department of Medical
Statistics of the LUMC.
Part 1
For the analysis of the inter- and intraobserver variability, Cohen
kappa coefficient will be used.
Part 2
Sample Size Calculation
For the prospective cohort, a sample size calculation has been
performed for both stages based on earlier research findings
[2,7].
• p-stage II patients: with a hazard ratio (HR) of 2.0, adjusted
for TNM, and a known percentage of stroma-high patients
in p-stage II of 20% to 25% [2,7], 114 recurrence events
with 90% power are necessary. To achieve 114 recurrence
events based on an event rate of 0.0575 per year (leading
to a 5-year probability of 75% and 3-year recurrence
probability of 84.2%), this leads to 722 patients.
• p-stage III patients: with an HR of 2.0, adjusted for TNM,
and a known percentage of stroma-high patients in stage
III of 30% to 35% [2,7], 97 recurrence events with 90%
power are necessary. To achieve 97 recurrence events based
on an event rate of 0.081 per year (leading to a 5-year
probability of 66.7% and 3-year recurrence probability of
78.4%), this leads to 450 patients.
To obtain 1172 evaluable p-stage II/III, approximately 1500
(+25%) patients will be registered, as all p-stage I and stage IV
patients will be excluded.
Statistical Analysis
Survival analysis will be performed using Kaplan-Meier survival
analysis and differences in survival distributions will be tested
using Log Rank statistics. The Cox proportional hazard model
is used to determine the HR of explanatory variables for overall
and disease-free survival (OS and DFS, respectively).
OS is defined as the time period between the date of surgery
and the date of death from any cause or the date of the last
follow-up. DFS is defined as the time between the date of
surgery and the date of any recurrence (local, regional, or distant
metastasis), date of new primary tumor, or date of death (any
cause). If no event occurs, DFS is calculated as the time period
until the date of last follow-up.
Ethical Considerations
This project is registered with the Netherlands Trial Registry
(NTR 7270). It will be conducted according to the Declaration
of Helsinki, Forteza, Brazil, October 2013.
As this research plan uses existing H&E-stained sections,
conventionally prepared for routine diagnostics, there is no risk
for the patient, and we expect no problems with the regulatory
authorities in the collaborating countries.
The UNITED study protocol has been approved by the Medical
Research Ethics Committee (MREC) of the LUMC, study
number p17.302. Before inclusion of patients in participating
countries, the protocol will be endorsed by the MREC of each
participating hospital.
Informed consent will be obtained from each eligible patient in
oral and written form before surgery.
Results
Part 1
The e-learning started mid-2018 and the first results will be
expected in the first half of 2019. The results will be presented
within 6 to 12 months after the last pathologist has completed
the e-learning module.
Part 2
The first patients were included at the end of 2018. In total,
1500 patients are needed, and the expected inclusion time is
about 3 years. A follow-up of 3 years is required. In late 2023,
the first results are expected, and they will be presented within
12 to 18 months after the last follow-up.
Discussion
The UNITED study has been developed to implement the TSR
in routine pathology, in addition to the TNM classification and
other known risk factors as an extra indicator for medical
treatment decision making.
Earlier research validated the prognostic value of TSR in
retrospective cohort studies. With the UNITED study, we aim
to validate the prognostic value of the TSR in a prospective
way.
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The results of the e-learning will contribute to a standardized
method and specifically trained pathologists. With the yearly
quality assessments, the quality of the scoring method will be
monitored and guaranteed.
Beside the tumor characteristics, as described in the TNM
classification, to determine the p-stage, the microenvironment
of the tumor is an important factor as well. The
microenvironment of a tumor is a wide spread of different cell
types. More tumor characteristics in the microenvironment are
studied, such as tumor budding [16-21], Immunoscore [22-24],
and desmoplastic reaction [19,25,26]. They are all independent
prognostic biomarkers for survival [16-26]. Outside this
protocol, we aim to study the relation between the different
(microenvironment) biomarkers to better understand the role
of the microenvironment and to further improve patient selection
for adjuvant treatment.
Treatment decision making in oncology is a multidisciplinary
process where medical oncologists play a pivotal role. These
professionals will also be involved by the introduction of the
TSR in daily clinical practice.
In conclusion, the UNITED study will, for the first time,
evaluate the TSR in a prospective cohort to prove its prognostic
value in stage II/III colon cancer. After completion of the
UNITED study, the TSR will have the highest level of evidence
for a prognostic marker and should be ready to use in the daily
practice of all gastroenterology pathologists and also ready to
play a role in clinical decision making.
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